


**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (Previously presented): A compound of formula (I):



(I)

wherein:

R<sub>x</sub> is H;

R<sub>y</sub> is H or C<sub>1</sub>-C<sub>4</sub> alkyl;

each R<sub>z</sub> is independently H or C<sub>1</sub>-C<sub>4</sub> alkyl;

X represents O;

Y represents OH or OR;

R is C<sub>1</sub>-C<sub>4</sub> alkyl;

Ar<sub>1</sub> is a phenyl ring or a 5- or 6-membered heteroaryl ring, each of which can be substituted with 1, 2, 3, 4 or 5 substituents depending upon the number of available substitution positions, each independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl), halo, hydroxy, pyridyl, thiophenyl, and phenyl optionally substituted with 1, 2, 3, 4 or 5 substituents each independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>4</sub> alkyl, and O(C<sub>1</sub>-C<sub>4</sub> alkyl); and

Ar<sub>2</sub> is a phenyl ring or a 5- or 6-membered heteroaryl ring, each of which can be substituted with 1, 2, 3, 4 or 5 substituents depending upon the number of available substitution positions, each independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl) and halo;

wherein each above-mentioned C<sub>1</sub>-C<sub>4</sub> alkyl group is optionally substituted with one or more halo atoms;  
or a pharmaceutically acceptable salt thereof.

2. (Currently amended): ~~A~~ The compound of claim 1, wherein:

Ar<sub>1</sub> is phenyl, pyridyl, pyrimidyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, thiophenyl, furanyl, imidazolyl, triazolyl, oxadiazolyl or thiadiazolyl, each of which can be substituted with 1, 2, 3, 4 or 5 substituents depending upon the number of available substitution positions, each independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl), halo, hydroxy, pyridyl, thiophenyl, and phenyl optionally substituted with 1, 2, 3, 4 or 5 substituents, each independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>4</sub> alkyl, or O(C<sub>1</sub>-C<sub>4</sub> alkyl); and

Ar<sub>2</sub> is phenyl, pyridyl, pyrimidyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, thiophenyl, furanyl, imidazolyl, or triazolyl, each of which can be substituted with 1, 2, 3, 4 or 5 substituents depending upon the number of available substitution positions, each independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl) and halo;

wherein each above-mentioned C<sub>1</sub>-C<sub>4</sub> alkyl group is optionally substituted with one or more halo atoms.

3. (Currently amended): ~~A~~ The compound of claim 1, wherein:


Ar<sub>1</sub> is unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substituents each independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl), halo, and phenyl optionally substituted with halo, C<sub>1</sub>-C<sub>4</sub> alkyl, or O(C<sub>1</sub>-C<sub>4</sub> alkyl); and

Ar<sub>2</sub> is unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substituents each independently selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), and halo;

wherein each above-mentioned C<sub>1</sub>-C<sub>4</sub> alkyl group is optionally substituted with one or more halo atoms.

4. (Currently amended): ~~A~~ The compound of claim 1, represented by the formula (II):

-- 5 --



(II)

wherein  $R_1$  and  $R_2$  are each independently selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), S(C<sub>1</sub>-C<sub>4</sub> alkyl), halo<sub>2</sub> and phenyl; and

$R_3$  is selected from the group consisting of H, C<sub>1</sub>-C<sub>4</sub> alkyl<sub>2</sub> and halo;

wherein each above-mentioned C<sub>1</sub>-C<sub>4</sub> alkyl group is optionally substituted with one or more halo atoms;

or a pharmaceutically acceptable salt thereof.


5. (Currently amended): ~~A~~ The compound of claim 4, wherein  $R_1$  is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, O(C<sub>1</sub>-C<sub>4</sub> alkyl), F, and Ph, wherein each above-mentioned C<sub>1</sub>-C<sub>4</sub> alkyl group is optionally substituted with one or more halo atoms.

6. (Currently amended): ~~A~~ The compound of claim 4, wherein  $R_2$  is H or F.

7. (Currently amended): ~~A~~ The compound of claim 4, wherein  $R_3$  is H.


8. (Currently amended): ~~A~~ The compound of claim 1, wherein Ar<sub>1</sub> includes a substituent attached at the 2-position.

9. (Currently amended): ~~A~~ The compound of claim 1 of the formula:




or a pharmaceutically acceptable salt thereof.

10. (Currently amended): ~~A~~ The compound of claim 1 of the formula:




or a pharmaceutically acceptable salt thereof.

11. (Currently amended): ~~A~~ The compound of claim 1 of the formula:



or a pharmaceutically acceptable salt thereof.

12. (Currently amended): ~~A~~ The compound of claim 1 of the formula:



or a pharmaceutically acceptable salt thereof.

Claim 13 (canceled).

Claim 14 (canceled).

Claim 15 (canceled).

Claim 16 (canceled).

17. (Withdrawn). A method for selectively inhibiting the reuptake of norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

18. (Withdrawn). A method for treating disorders associated with norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.


19. (Canceled).

20. (Withdrawn). A method of claim 18, wherein the disorder is attention-deficit hyperactivity disorder.

21. (Withdrawn). A method of claim 18, wherein the disorder is schizophrenia.

22. (Previously presented): A pharmaceutical composition, comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent, excipient, or carrier.

23. (Withdrawn). A compound of formula (IV):



(IV)

wherein Pg represents an N-protecting group and all other variables are as defined for formula (I) in claim 1.